Pharmaceutical - Diabetes, Mergers & Acquisitions

Filter

Popular Filters

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

16-12-2013

Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus

08-11-2013

Salix Pharmaceuticals has entered into a definitive merger agreement to acquire all the outstanding common…

DiabetesGastro-intestinalsGlumetzaMergers & AcquisitionsPharmaceuticalRare diseasesRuconestSalix PharmaceuticalsSantarus

Unigene and Nordic Bioscience amend JDV accord; Amgen Vectibix China deal

10-05-2013

USA-based Unigene Laboratories (PINK: UGNE) has entered into an equity transfer and exclusive license…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDiabetesLicensingMergers & AcquisitionsNordic BioscienceOncologyPharmaceuticalUGP302Unigene LabsVectibixZhejiang Beta Pharma

Evotec acquires Cell Culture Service GmbH; expands deal with AstraZeneca

07-01-2013

German biotech firm Evotec (EVT: TecDAX) has acquired all the shares in Cell Culture Service GmbH (CCS),…

AstraZenecaBiotechnologyCell Culture Service GmbHDiabetesEvotecLicensingMedImmuneMergers & AcquisitionsPharmaceutical

Amylin seduced by $5.3 billion bid from Bristol-Myers; AstraZeneca chips in for share of the action

02-07-2012

Having rejected a media reported $22 a share offer from the company earlier this year, US biotech firm…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbBydureonByettaDiabetesEli LillyMergers & AcquisitionsPharmaceutical

Sanofi's Aubagio reduces MS relapse; firm aims to build diabetes portfolio

01-06-2012

Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) today reported top-line results from…

AubagioBiotechnologyDiabetesGenzymeMergers & AcquisitionsNeurologicalPharmaceuticalResearchSanofiteriflunomide

New Actavis/Bioton alliance aims to shake up diabetes market

31-01-2012

Icelandic generics drugmaker Actavis and Poland’s Bioton (WSE: BIO) have formed a joint venture…

ActavisBiotonDiabetesGenericsMarkets & MarketingMergers & AcquisitionsPharmaceutical

In India, Lilly and Boehringer link for diabetes drug marketing; GSK eyeing acquisitions

04-10-2011

The Indian subsidiaries of US drug major Eli Lilly (NYSE: LLY) and independent German pharma company…

Asia-PacificBoehringer IngelheimDiabetesEli LillyGlaxoSmithKlineMarkets & MarketingMergers & AcquisitionsPharmaceutical

Back to top